Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Inclusion Criteria:

* Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.
* Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse/progression having attained a CR, PR, or stable disease post reinduction therapy.
* Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for patients \> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
* Life Expectancy Patients must have a life expectancy of \> 6 weeks.
* Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

  1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).
  2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.
* Organ Function Requirements

Adequate Renal Function Defined As:

* Creatinine clearance or radioisotope GFR \> 60 mL/min/1.73 m2 or
* A serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female

* 12 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4
* 16 years 1.7 1.4

  * Adequate Liver Function Defined As:

    * Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age, and
    * SGOT (AST) or SGPT (ALT) \< 3 x upper limit of normal (ULN) for age for presumed hepatic leukemia or lymphoma.
  * Adequate Cardiac Function Defined As:

    * Shortening fraction of \> 27% by echocardiogram, or
    * Ejection fraction of \> 50% by radionuclide angiogram.
  * Adequate Pulmonary Function Defined As:

    • Normal respiratory rate for age and a pulse oximetry \> 94% on room air unless due to underlying malignancy.
  * Peripheral Blood Stem Cell Collection

    • Patients have a target of 5.0 x 106 CD34 (minimum of 2.5 x 106 CD34) PBSC collected and cryopreserved prior to start of myeloablative conditioning
  * All patients and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria:

* Patient may not have had a prior stem cell transplant
* Patients must not have active CNS lymphoma
* Other concurrent investigational agents for treatment of B-cell lymphoma
* Pregnancy and/or active Breast Feeding
* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.
* Patient must not have an uncontrolled infection.
* Patient must not have ≥ Grade 3 neuropathy.